Abstract: A method for treating a neuroendocrine tumor is disclosed, which includes administering a first dose of 111In-pentetreotide to a subject having the neuroendocrine tumor; and administering a second dose of 111In-pentetreotide to the subject after a selected duration has elapsed after the administering of the first dose, wherein the first dose and the second dose are each about 400 mCi or higher, and wherein the selected duration is at least a week. In another method, the first dose and the second dose are each about 500 mCi and the selected duration is between 10 and 12 weeks. The method may further include administration of a third dose. A composition for treating a neuroendocrine tumor includes 111In-pentetreotide having a radioactivity of about 400 mCi or higher in a single dose.

Abstract: The present invention provides novel imaging agents for clinical diagnosis of injuries and diseases, in the form of a radionuclide in spatial proximity to a substantially pure stereoisomer of a fatty acid analog. The invention also provides methods for using the novel imaging agents, and kits containing one or more of the novel imaging agents of the invention.

Abstract: The present invention relates to a biological tissue examination agent comprising hemoglobin labeled with 15O2 and a method for producing the same. More specifically, the present invention relates to a biological tissue examination agent for diagnosing a cause or condition of a disease by detecting oxygen metabolism in a biological tissue using hemoglobin labeled with 15O2, and a method for producing the same. The present invention also relates to a method for detecting oxygen metabolism in a biological tissue.

Abstract: The invention provides novel peptide prodrugs that contain cleavage sites specifically cleaved by human kallikrein 2 (hK2). These prodrugs are useful for substantially inhibiting the non-specific toxicity of a variety of therapeutic drugs. Upon cleavage of the prodrug by hK2, the therapeutic drugs are activated and exert their toxicity. Methods for treating cell proliferative disorders are also featured in the invention.

Abstract: The invention provides anti-Robo4 antibodies, and compositions comprising the antibodies and methods of using these antibodies, including diagnostic and therapeutic methods.

Abstract: The invention relates to a method for determining the kinetics of action of a cholinergic neurotoxin as well as a method for determining the quantity of neurotoxin in a sample.

Abstract: The present invention relates to drug screening assays, therapeutic protocols and pharmaceutical compositions designed to target non-receptor tyrosine family kinases and components of the tyrosine kinase family signal transduction pathways. This includes primarily diseases or conditions associated with immune responses and can include treatment for cancers as well as various immune disorders. The invention reports a novel substrate SH2 domain docking mechanism apart from the kinase active site that is required for appropriate tyrosine phosphorylation by these tyrosine kinases.

Abstract: The present invention provides for the treatment of primary headache disorders, particularly migraine, using antagonists of the EP4 receptor for prostaglandin E2. Particular EP4 receptor antagonists include azole compounds of formula (I): wherein R1 is a group such as lower alkyl substituted with carboxy; R2 is hydrogen or lower alkyl, R3 and R4 are aryl optionally substituted with halogen, Q is in which -A1- is a single bond or lower alkylene, is a cyclo group, -A3- is a single bond or lower alkylene, and X is O, NH or S; or a salt or its solvate thereof.

Abstract: The present invention provides methods of treating inflammatory diseases/disorders in a subject by inhibiting/antagonizing TREM-1 expression/activity/signal transduction and/or DAP12/TyroBP expression and/or activity. Methods of detecting the presence of inflammatory disease in a subject by detecting TREM-1 and/or DAP12/TyroBP expression and/or activity in the subject or a sample obtained therefrom, wherein increased expression or activity is indicative of the inflammatory disease are also included. The present invention further provides methods for assessing the efficacy of a TREM-1-modulating agent administered to a patient by detecting levels of secreted phosphoprotein 1 (SPP1) and/or one or more other biomarkers in the patient or in a sample from the patient.

Abstract: Methods and compositions for modulating apoptosis by acting on the c-Jun-N-terminal kinase (JNK) pathway and assays for the isolation of agents capable of modulating apoptosis, including modulators of the JNK pathway are disclosed. A method of modulating JNK pathway independent of Gadd46? is disclosed. Methods and compositions are presented for the preparation and use of novel therapeutic compositions for modulating diseases and conditions associated with elevated or decreased apoptosis.

Abstract: The present invention comprises minimally invasive methods useful in the treatment of liver cancer. The method of the present invention comprises administering to an individual with liver cancer an injectable, echogenic nanocapsule and/or microcapsule wherein the nanocapsule and/or microcapsule comprises a therapeutic agent, a targeting moiety, or a combination thereof. The method of the present invention further comprises monitoring the distribution of the nanocapsule and/or microcapsule using ultrasound. The method of the invention delivers a therapeutic agent to a liver cancer cell either by biodegradation of a nanocapsule and/or microcapsule comprising a therapeutic agent, or by altering the biodegradation of a nanocapsule and/or microcapsule using ultrasound.

Abstract: A composition comprising an albumin-based colloid composition having at least one protected thiol region, method of making the same, and method for use, including treating hypovolemic conditions such as capillary leak syndrome and shock, are disclosed. The composition also is modified with an indicator reagent such as chromophores.

Abstract: The invention relates to a form of administration which is thermoformed without extrusion, comprising at least one synthetic or natural polymer having a resistance to breaking of at least 500 N in addition to one or several active ingredients with a misuse potential and, optionally physiologically compatible auxiliary substances. The invention also relates to a method for the production thereof.

Abstract: Improved aqueous foaming topical compositions for the application to the human body particularly to the skin which composition provides both a cleaning benefit, and a durable antimicrobial benefit.

Abstract: The present invention provides a method for inducing sleep, by nasally administrating to a subject in need thereof a pharmaceutical composition containing zolpidem, a pharmaceutically acceptable salt thereof, or a combination thereof, and a pharmaceutically acceptable nasal carrier in liquid form.

Abstract: A novel pharmaceutical composition comprising a mixture of higher primary aliphatic alcohols from (24) to (39) carbon atoms; at least one another component selected from resins and pigments, hydrocarbons, esters, ketones and aldehydes, and phenolic compounds, and HMG CoA reductase inhibitor, its salts, analogs or derivatives thereof, preferably statins, optionally with pharmaceutically acceptable excipients, and process of preparation of such composition is provided. Also provided are method of treatment and use of such composition for reducing abnormal lipid parameters associated with hyperlipidemia.

Abstract: The invention relates to the quinuclidine compounds of formula I having quaternary ammonium group, its preparation, and the pharmaceutical composition comprising an effective amount of the compound of formula I. The compound and the composition are used to prevent and treat the diseases by blocking acetylcholine receptor. Wherein: R1 is selected from C1-12 saturated straight-chain alkyl and cycloalkyl; R2 is selected from C1-12 saturated straight-chain alkyl or straight-chain alkyl; X is selected from halogen ion, organic and inorganic acid radical.

Abstract: Substituted azaspiro derivatives of the Formula: are provided, in which variables are as described herein. Such compounds may be used to modulate ligand binding to histamine H3 receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of central nervous system (CNS) and other disorders in humans, domesticated companion animals and livestock animals. Compounds provided herein may be administered alone or in combination with one or more other CNS agents to potentiate the effects of the other CNS agent(s). Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting histamine H3 receptors (e.g., receptor localization studies).

Abstract: The invention relates to pressurized metered dose inhalers (MDIs) in which all or part of the internal surface is lined with an inert organic coating and which contain a formulation which comprises TA 2005.

Abstract: The invention relates to hedonistically pleasing oral malodour counteracting compositions including flavour compositions and oral care products, methods to form such compositions and methods to counteract oral malodour. The compositions comprises 4 or more of oral malodour counteracting actives in a total concentration of at least 20% (w/w) based on the total concentration of flavour ingredients, and an individual concentration of 1% or more per oral malodour counteractant, based on total flavour ingredients. The maximum concentration of any individual oral malodour counteracting active based on the total of oral malodour counteracting actives is 70%. The identified oral malodour counteracting actives are various flavour compounds and natural ingredients.

Abstract: A dentifrice composition comprising at least one phase, wherein said dentifrice is packaged in a generally transparent container, and wherein the combination of the dentifrice and the container and/or at least one packaging layer forms a pattern.

Abstract: A multi-phase dentifrice composition comprising at least two visually distinct phases, wherein said visually distinct phases are packaged in a generally transparent container, wherein at least one phase is in physical contact with another phase, and wherein the visually distinct phases form the appearance of at least one character.

Abstract: A multi-phase dentifrice composition comprising at least two visually distinct phases wherein said visually distinct phases are packaged in a generally transparent container, wherein at least one phase is in physical contact with another phase, wherein all visually distinct phases are opaque, and wherein the visually distinct phases form any of a variety of patterns, excepting stripes.

Abstract: A multi-phase dentifrice composition comprising at least two visually distinct phases wherein said visually distinct phases are packaged in a generally transparent container, at least one phase is in physical contact with another phase, all visually distinct phases are opaque, and the visually distinct phases form alternating bands wherein at least one band is oriented in a direction not parallel to the longitudinal axis of the container or at least one band is oriented in a direction not parallel to the direction that the composition is dispensed from the container.

Abstract: A multi-phase dentifrice composition comprising at least two visually distinct phases wherein said visually distinct phases are packaged in a generally transparent container, at least one phase is in physical contact with another phase, at least one visually distinct phase is generally transparent, and at least one visually distinct phase forms a coil through at least one other visually distinct phase.

Abstract: The present aspects relate to a mouthwash developed to reduce and/or avoid the formation of tonsilloliths, heretofore unknown to the art, to facilitate the removal and to diminish the new formation of tongue coating and to reduce the concentration and formation of volatile sulfur compounds. In a preferred aspect, the compound includes Hydrogen peroxide, Citric acid, flavorizer, Sodium benzoate, Cetylpyridinium chloride, colorant, Sodium fluoride, Methyl paraben, Polisorbate 20 (Tween 20), Dimethicone, Sodium saccharine, Sorbitol and demineralized water. The compound may be used in mouth washing and gargling so that the active ingredients can be released.

Abstract: Disclosed are oral care compositions comprising selected surface-active organophosphate compounds and methods of use to provide protection of teeth from erosion caused by the action of chemicals, such as harsh abrasives and acids. The surface-active organophosphate compounds are substantive to teeth, the phosphate groups binding the calcium in teeth and thus preventing loss of calcium from dissolution when contacted with acids. The organophosphate compound may also deposit a protective surface coating that prevents contact of teeth with erosive challenges.

Abstract: The invention relates to a rooibos extract prepared from unfermented rooibos raw material by means of a solvent extraction, with an increased aspalathin content that is at least 5 wt %, cosmetic agents prepared from such a rooibos extract, and a process for the preparation of such a rooibos extract having an increased aspalathin content and preferably a reduced chlorophyll content.

Abstract: Topically applicable, water-resistant cosmetic or dermatological compositions well suited for the UV-photoprotection of human skin and/or hair comprising an effective UV— photoprotecting amount of: (a) at least one UV screening agent; (b) at least one select copolymer; and, optionally (c) other cosmetically acceptable ingredients. The present invention also relates to personal care compositions comprising at least one select copolymer and other cosmetically acceptable ingredients.

Abstract: Topically applicable, water-resistant cosmetic or dermatological compositions well suited for the UV-photoprotection of human skin and/or hair comprising an effective UV-photoprotecting amount of: (a) at least one UV screening agent; (b) at least one random terpolymer; and, optionally (c) other cosmetically acceptable ingredients. The present invention also relates to personal care compositions comprising at least one random terpolymer and other cosmetically acceptable ingredients.

Abstract: The invention concerns a cosmetic product for lip make-up or care in the form of an anhydrous film comprising: a) at least one water-soluble polymer, and b) at least one dye. Said anhydrous film dissolves in contact with saliva to provide lip make-up or treatment.

Abstract: A stick or soft solid suspension product comprising: (a) 0.01-20 weight % of a polyacrylate superabsorbent polymer (sodium salt), with a salt or ionic strength tolerance under a Baseline Absorption Test sufficient to give at least 25 weight % water absorption; (b) 10-88 weight % of a volatile silicone having a flash point of 100° C. or less; (c) a selected gelling agent; provided that the water content is ?2 weight % and the ratio of superabsorber to active salt is in the range of 0.13-4:1.

Abstract: The invention describes the use of a hydrophobic zeolite, that contains an active component, especially a disinfection element, as ethanol, iodine, phenol, cresol or hydrogen peroxide, in a composition for non-medical treatment of the skin, for example as a deodorant. The invention also describes the use of a hydrophobic zeolite, that contains an active component, especially a disinfection element, as ethanol, iodine, phenol, cresol or hydrogen peroxide, for manufacturing of a pharmaceutical preparation for treatment of skin related conditions and diseases, as skin infections. The hydrophobic zeolite is especially selected from that group that comprises silicalite, or hydrophobic ZMS-5, hydrophobic mordenite and hydrophobic zeolite Y.

Abstract: A cosmetic and personal care composition comprising a hydrophobically functionalised polyhydric dendritic macro-molecule built up from polyester or polyether units or mixtures thereof.

Abstract: To provide a vinylpyrrolidone/vinyl acetate copolymer which is extremely reduced in thermal yellowing and is usable even at high temperatures and which can dissolve in water to give a transparent solution. The vinylpyrrolidone/vinyl acetate copolymer of the present invention has a residual vinylpyrrolidone content of 100 ppm or less relative to a solid content of the copolymer. A 5% by weight aqueous solution of the copolymer has an NTU value of 4.0 or less. A 50% aqueous solution of the copolymer has a Hazen color number (APHA) according to JIS-K3331 of 350 or less, the Hazen color number being measured by the following accelerated test.

Abstract: The invention relates to a hair treatment product containing a1) alkyl ether sulfate or a2) alkyl sulfate or the mixture thereof, b) secondary alkane sulfonate, c1) betaine or c2) ether carboxylate or the mixture thereof, d) at least one non-ionic surfactant, and e) a cationic surfactant.

Abstract: The method for making a hair pomade composition includes the steps of melting petroleum jelly over a heated surface and then mixing sesame seed oil, meadowfoam seed oil, pumpkin seed oil, Cyprus oil, basil sweet oil, Rosemary oil, black pepper oil, lemon oil, and Anise oil with the melted petroleum jelly into a mixture. Thereafter, the all-natural hair pomade mixture is solidified.

Abstract: The invention describes DOPA functionalized, branched, polyalkylene oxide materials that are useful as adhesives.

Abstract: Substantially homogeneous topical preparations for cosmetic, veterinary, and pharmaceutical use comprise at least one active ingredient solubilized in a novel composition base. The composition base comprises solubilized allantoin at a level of at least 0.5% and urea at a level of at least 10% in an aqueous vehicle.

Abstract: The present invention relates to a hyaluronidase inhibitor containing poly-gamma-glutamic acid (PGA) as an active ingredient, a composition for maintaining skin elasticity and a composition for improving allergy, wherein each of the compositions contains PGA as an active ingredient. The inventive compositions containing PGA are effective in maintaining skin moisturization and skin elasticity by effectively inhibiting the activity of hyaluronidase which is an enzyme that degrades hyaluronic acid present in the skin dermis. Also, the compositions can relieve allergic symptoms by inhibiting the permeability of inflammatory cells.

Abstract: The present invention describes compositions, devices, and methods for the production, use and administration of the composition having a non-thermoreversible block copolymer composition.

Abstract: Comblike, surfactant polymers for changing the surface properties of biomaterials are provided. Such surfactant polymers comprise a polymeric backbone of repeating monomeric units having functional groups for coupling with side chains, a plurality of hydrophobic side chains linked to said backbone via the functional groups, and a plurality of hydrophilic side chains linked to said backbone via the functional groups. The hydrophobic side chains comprise an alkyl group comprising from 2 to 18 methylene groups. The alkyl groups are linked to the polymeric backbone through ester linkages, secondary amine linkages, or, preferably, amide linkages.

Abstract: The present disclosure provides medicinally active extracts and fractions, and methods for using the same to increase eukaryotic cell adhesion, to increase differentiation of eukaryotic cells to produce increased numbers of B cells dendritic cells and chodrocytes, and to maintain undifferentiated hematopoietic cells. These methods and useful for modulating immune response, modulating hematopoietic activity, and engineering certain types of eukaryotic tissues.

Abstract: The invention provides a natural killer cell, NK-92, modified to express a CD16 receptor or an inhibitory killer cell immunoglobulin-like receptor (KIR) on a surface of the cell. In examples, the NK-92 cell is further modified to co-express an associated accessory signaling protein such as Fc?RI-? or TCR-?, chemokines, or cytokines such as interleukin-2 (IL-2) or interleukin-15 (IL-15). Additional methods are disclosed for various assays, assessments, and therapeutic treatments with the modified NK-92 cells.

Abstract: In part, the present invention relates to a compound or polymer comprising a non-protein-binding moiety and at least one protein-binding group. The present invention relates to a method of screening compounds or polymers for the property of inhibiting protein aggregation in solution, a method of preparing a compound or polymer having the property of protein aggregation inhibition in solution, a method of classifying a compound or polymer as either inhibitory of protein aggregation in solution or not inhibitory of protein aggregation in solution, and to a method of determining the preferential binding coefficient, ?XP, of an additive in a protein solution. The present invention also relates to a method of suppressing or preventing aggregation of a protein in solution, a method of decreasing the toxicological risk associated with administering a protein to a mammal in need thereof, and a method of facilitating native folding of a recombinant protein in solution.

Abstract: Disclosed are compounds, compositions and methods for treating Flaviviridae family virus infections.

Abstract: Described are microorganisms which are able to suppress the production of malodorous compounds by axillary bacteria. Also described are compositions comprising such microorganisms as well as the use of such micoorganisms in cosmetic, prophylactic or therapeutic applications.

Abstract: The present invention relates to a DNA vaccine consisting of a vector expressing a part or the whole of a polypeptide regulating production of an inflammatory cytokine, a pharmaceutical composition comprising the DNA vaccine, and a method of preventing or treating an inflammatory disease by using the pharmaceutical composition.

Abstract: The present disclosure provides nucleic acid constructs encoding one or more polypeptides containing at least one glycosaminoglycan chain, such as, but not limited to, a proteoglycan polypeptide, and methods for delivering to the site of a wound or cutaneous injury at least one nucleic acid construct encoding one or more such polypeptides, such that the expressed polypeptide is glycated by glycosaminoglycan chains through the normal physiological processes of the subject at the site of administration to produce a functional proteoglycan polypeptide for the healing of the wound or other cutaneous injury. The delivered nucleic acid construct is transcribed, translated and post-translationally modified by the addition of glycosaminoglycan chains (referred herein as “decoration” or “glycation”) to produce a decorated polypeptide.

Abstract: The invention provides methods of treating neoplasia using combinations of target cell-specific replication competent adenoviral vectors and chemotherapy, radiation therapy or combinations thereof. The adenoviral vectors are target cell-specific for the particular type of neoplasia for which treatment is necessary and the combination with the chemotherapy and/or radiation leads to synergistic treatment over existing adenoviral therapy or traditional chemotherapy and radiation therapy.